Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: Tentative disc diffusion criteria and quality control

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 6, 2005, Pages 944-949

  Brown, Steven D ^a   Traczewski, Maria M ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

Breakpoints; QC; Spectum

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; DORIPENEM; IMIPENEM; MEROPENEM; METICILLIN; PENICILLIN G;

ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFUSION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; REFERENCE VALUE; SPECIES DIFFERENCE; STAPHYLOCOCCUS; STREPTOCOCCUS;

CARBAPENEMS; DIFFUSION; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL;

EID: 21244474420     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki134     Document Type: Article

References (16)

1. Brown S, Traczewski M. Doripenem: in vitro potency, spectrum of activity, MIC and disc breakpoints. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract E-2016, p. 175. American Society for Microbiology, Washington, DC, USA
2. Traczewski MM, Brown SD. In vitro activity of doripenem versus 194 strains of P. aeruginosa and B. cepacia from both cystic fibrosis and non-cystic fibrosis patients. In: Abstracts of the One Hundred-fourth General Meeting of the American Society for Microbiology, New Orleans, LA 2004. Abstract A-141, p. 28. American Society for Microbiology, Washington, DC, USA.
3. Tsuji M, Ishii Y, Ohno A et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 1998; 42: 94-9.
4. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004; 48: 1313-9.
5. Mikamo H, Izumi K, Hau YZ et al. In vivo and in vivo antibacterial activities of a new injectable carbapenem, S-4664, against gynaecological pathogens. J Antimicrob Chemother 2000; 46: 471-4.
6. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 3086-92.
7. Ge Y, Wikler MA, Sahm DF et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004; 48: 1384-96.
8. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
9. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disc Susceptibility Tests: Approved Standard M2-A8. NCCLS, Wayne, PA, USA, 2003.
10. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Approved Standard M11-A6. NCCLS, Wayne, PA, USA, 2004.
11. National Committee for Clinical Laboratory Standards. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters: Approved Standard M23-A2. NCCLS, Wayne, PA, USA, 2001.
12. Bhavnani SM, Hammel JP, Cirincione BB et al. PK-PD target attainment with Monte Carlo Simulation (MCS) as decision support of phase 2/3 dosing strategies for the clinical development of doripenem (DOR). In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-11, p. 2. American Society for Microbiology, Washington, DC, USA.
13. Thye DA, Kilfoil T, Leighton A et al. A Phase 1 study to evaluate safety, tolerability and pharmacokinetics in a western healthy volunteer population. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-21, p. 5. American Society for Microbiology, Washington, DC, USA.
14. Andes DR, Keim S, Craig WA. In vivo pharmacodynamic activity of a new carbapenem, doripenem (DOR), against multiple bacteria in a murine thigh infection model. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-309, p. 10. American Society for Microbiology, Washington, DC, USA.
15. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Approved Standard M100-S10. NCCLS, Wayne, PA, USA, 1999.
16. Gavan TL, Jones RN, Barry AL et al. Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disc diffusion susceptibility tests: a collaborative study. J Clin Microbiol 1981; 14: 67-72.